Zevra Therapeutics (ZVRA) Interest & Investment Income (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Interest & Investment Income of $3.6 million for Q1 2026, up 109.64% on a QoQ basis from $1.7 million in Q4 2025, and up 560.96% year-over-year from $543000.0 in Q1 2025.
Zevra Therapeutics (ZVRA) Interest & Investment Income (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- Quarterly Interest & Investment Income rose 560.96% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 458.52% YoY) and the FY2025 annual result came in at $6.9 million, up 219.36% from the prior year.
- Interest & Investment Income was $3.6 million for Q1 2026 at Zevra Therapeutics, up from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.6 million in Q1 2026 and bottomed at -$73000.0 in Q4 2024.
- A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 8466.67% — and 2024, when it sank 134.76%.
- Zevra Therapeutics' Interest & Investment Income stood at $1.0 million in 2022, then tumbled by 79.63% to $210000.0 in 2023, then sank by 134.76% to -$73000.0 in 2024, then soared by 2445.21% to $1.7 million in 2025, then soared by 109.64% to $3.6 million in 2026.
- Business Quant data shows ZVRA's Interest & Investment Income at $3.6 million in Q1 2026, $1.7 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn | 3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.38 Mn |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | -73,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | 753,000.00 |
| Mar 31, 2022 | 107,000.00 |
| Dec 31, 2021 | 125,000.00 |
| Sep 30, 2021 | 137,000.00 |
| Jun 30, 2021 | -9,000.00 |